Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (4)	3/6/2001 8:43:37 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 161

David, I could be totally off, but I think Darwin was sold to a UK company. That was a Hood/Gates deal if I recall. PSBJ reports that SG was founded by Perry Fell and Clay Siegall, scientists at the BMS Pharmaceutical Research Institute in Seattle until it closed in 1997. They established Seattle Genetics the following year, licensing some ab technology from BMS. I have no insight on this one. But if I recall, it has been trying to tap the public markets for a long, long time. Given the state of things today, they must have run out of VC and angel $ and hope all at once. What are ya buying these days? --Wilder

To: Elmer who wrote (4)	6/5/2001 5:05:22 PM
From: Icebrg	Read Replies (1) \| Respond to of 161

David Sorry, I haven't been following this thread until Nigel was kind enough to provide a link today for us ImmunoGen folks. Seattle Genetics is actually a spin-off from Bristol-Myers Squibb Co. Signals Magazine did last year carry a story with some background information. Ice "Ugly Duckling Start-Ups Take Flight One way to start a biotech company is with a product another company doesn't want to develop. It can pay off big for those with the vision, drive and guts to turn somebody else's ugly duckling into a pharmaceutical swan." signalsmag.com